Biomarker ID | 1316 |
PMID | 24448834 |
Year | 2014 |
Biomarker | FRK [SNP: rs171866: AA versus gg/gA] |
Biomarker Basis | Mutation Based |
Biomolecule | Mutation |
Source | Blood |
Subjects | Humans |
Regulation | Increased risk of Progression |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.52 (95% CI: 1.08–2.13) |
Effect on Pathways | Pathways include: RPS6KL1 human kinase ARCHS4 coexpression, STK33 human kinase ARCHS4 coexpression, SGK3 human kinase ARCHS4 coexpression, MAP4K5 human kinase ARCHS4 coexpression, NTRK3 human kinase ARCHS4 coexpression |
Experiment | Progression Vs No Progression During ADT |
Type of Biomarker | Prognostic |
Cohort | 321 patients with localized prostate cancer who underwent radical prostatectomy (RP) as initial treatment and 605 patients with advanced prostate cancer on androgen-deprivation therapy (ADT) |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p=0.015 |
Method Used | MALDI-TOF |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |